SRX GLOBAL INC
SRXHNYSE AMERICANTrading Snapshot
- Day Range
- $1.04 – $1.09
- 52-Week Range
- $0.96 – $42.61
- Volume (shares)
- 169,080
- Avg Volume (shares)
- —
- Shares Outstanding
- 9.8M
- Next Earnings
- 2026-12-25
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $3M
- P/E Ratio
- -0.0
- P/S Ratio
- -0.3x
- EPS (TTM)
- $-3.54
- Dividend Yield
- 4.63%
- Dilution (1yr)
- −65.2%
SRX GLOBAL INC
SRXH
StockOtter · stockotter.spaceAbout SRX GLOBAL INC
SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership New platform to be launched with m
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologi
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX's proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones fo
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in